Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod in Chinese patients with primary membranous nephropathy
NCT05810961Phase 2Terminated
- Sponsor
- argenx
- Start
- Feb 2023
- Primary completion
- Aug 2024
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary membranous nephropathy (PMN) comparing Efgartigimod with Placebo (2 arms). Primary endpoint: Change from baseline in urine protein creatinine ratio (UPCR) in anti-PLA2R antibody seropositive population at 24 weeks. Started Feb 2023; status: terminated.
02
Drugs
efgartigimod alfa
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT05810961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05810961.